SEC For	rm 4 FORM	Л	UNITI	ED STA		S SE	ECL	IRITI	ES AI	ND	EXCHA	NGE C	оммі	SSION					
		-	•••••						ngton, D				•			OMB AP	PRO	VAL	
Check this box if no longer subject to STATEMEN						IT OF CHANGES IN BENEFICIAL OWNERSH									OMB Number: 3235-0287 Estimated average burden				
	tions may contir ction 1(b).	nue. See		Fil	led pur or	suant f	to Seo on 30	ction 16(a (h) of the	a) of the Investr	Secu nent C	rities Exchan company Act	ge Act of 1 of 1940	934		hours	per respons	e:	0.5	
1. Name and Address of Reporting Person [*] Secora Michael					<u>R</u>	2. Issuer Name and Ticker or Trading Symbol <u>RECURSION PHARMACEUTICALS</u> , <u>INC.</u> [RXRX]									Relationship of Reporting Person(s) to Issuer heck all applicable) Director 10% Owner				
(Last)	, , , , , , , ,				3.	3. Date of Earliest Transaction (Month/Day/Year) 07/09/2024								Cfficer (give title Other (specify below) Other Specify Delow)					
C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET					4.									Individual or Joint/Group Filing (Check Applicable e)					
(Street) SALT LAKE CITY UT 84101						Form filed by One Reporting Person Form filed by More than One Reporting Person													
(City)								. ,			nsaction was m			aat inatructia	n or writton t	alan that is i	ntondo	d to	
					V	satisf	fy the a	affirmative	defense	e condi	tions of Rule 1	0b5-1(c). S	ee Instructio	n 10.			Interlued		
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day					ction	2A. Exe	Deen ecutio ny		3. Transaction Code (Instr. 8)		4. Securities	Acquired (A) or (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Followi		6. Owners Form: Dir (D) or Indi (I) (Instr. 4	ect rect	7. Nature of Indirect Beneficial Ownership	
							(,			v	Amount	(A) or (D)	Price	e Reported Transactior (Instr. 3 and				(Instr. 4)	
Class A Common Stock 07/09/20					2024	124			M ⁽¹⁾		39,375	Α	\$2.22	1,30	7,218	D			
Class A Common Stock 07/09/20					2024)24			S ⁽¹⁾		15,000	D	\$7.3185	(2) 1,292,218		D			
Class A Common Stock 07/10/20					2024)24			M ⁽¹⁾		39,375	Α	\$2.22	1,331,593		D			
Class A Common Stock 07/10/20)24			S ⁽¹⁾		15,000	D	\$7.2384			D			
			Table II								posed of, convertil			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deer Execution if any (Month/I	on Date,	4. Transaction Code (Instr. 8)				6. Date Exercis: Expiration Date (Month/Day/Yea		te of Securi ear) Underlyi		g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	ly Dire or Ir (I) (I) (I	nership n: ct (D) ndirect nstr. 4)	Beneficial Ownershi (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$2.22	07/09/2024			M ⁽¹⁾			39,375	(4))	03/03/2030	Class A Common Stock	39,375	\$0	692,01	0	D		
Stock Option (Right to Buy)	\$2.22	07/10/2024			M ⁽¹⁾			39,375	(4))	03/03/2030	Class A Common Stock	39,375	\$0	652,63	5	D		
Stock Option (Right to Buy)	\$2.22								(5))	03/03/2030	Class A Common Stock	0		685,17	7	D		
Stock Option (Right to									02/04/	2022	02/04/2032	Class A Common	0		3,914		D		
Buy)	\$11.4								02/04/.			Stock							
	\$11.4 \$11.4								(6)		02/04/2032	Class A Common Stock	0		116,68	4	D		
Buy) Stock Option (Right to)	02/04/2032	Class A Common	0		116,68- 404,85		D		

Explanation of Responses:

1. Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2024.

2. This transaction was executed in multiple trades at prices ranging from \$7.165 to \$7.44 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction was executed in multiple trades at prices ranging from \$7.155 to \$7.50 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. 4. The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events. 6. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

7. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

8. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

Remarks:

/s/Jonathan Golightly, attorney-07/11/2024

in-fact ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{5.} The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter.